Comparative study analyzing survival and safety of bevacizumab/carboplatin/paclitaxel and cisplatin/pemetrexed in chemotherapy-naïve patients with advanced non-squamous bronchogenic carcinoma not harboring EGFR mutation

Comparative study analyzing survival and safety of bevacizumab/carboplatin/paclitaxel and cisplatin/pemetrexed in chemotherapy-naïve patients with advanced non-squamous bronchogenic carcinoma not harboring EGFR mutation

Item

http://www.wikidata.org/entity/Q36985910

Q36985910

about

Comparative study analyzing survival and safety of bevacizumab/carboplatin/paclitaxel and cisplatin/pemetrexed in chemotherapy-naïve patients with advanced non-squamous bronchogenic carcinoma not harboring EGFR mutation

Item

http://www.wikidata.org/entity/Q36985910

description

2013 nî lūn-bûn

@nan

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

2013年论文

@zh

2013年论文

@zh-cn

name

Comparative study analyzing su ...... ma not harboring EGFR mutation

@en

type

Item

label

Comparative study analyzing su ...... ma not harboring EGFR mutation

@en

prefLabel

Comparative study analyzing su ...... ma not harboring EGFR mutation

@en

P1476

Comparative study analyzing su ...... ma not harboring EGFR mutation

@en

P2093

Amr Sakr

http://www.w3.org/2001/XMLSchema#string

Tamer El-Nahas

http://www.w3.org/2001/XMLSchema#string

Yasser Abdel Kader

http://www.w3.org/2001/XMLSchema#string

P2860

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer

Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer

Prediction of creatinine clearance from serum creatinine

Toxicity and response criteria of the Eastern Cooperative Oncology Group

Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer

Phase III randomized trial comparing three platinum-based doublets in advanced non-small-cell lung cancer.

Randomized, multinational, phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced non-small-cell lung cancer: the TAX 326 study group.

Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma.

Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer.

P304

803-809

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2147/OTT.S45906

http://www.w3.org/2001/XMLSchema#string

P407

English

P478

http://www.w3.org/2001/XMLSchema#string

P50

Thierry Le Chevalier

P577

2013-07-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

23836994

http://www.w3.org/2001/XMLSchema#string

P921

bevacizumab

P932

3702548

http://www.w3.org/2001/XMLSchema#string

Comparative study analyzing survival and safety of bevacizumab/carboplatin/paclitaxel and cisplatin/pemetrexed in chemotherapy-naïve patients with advanced non-squamous bronchogenic carcinoma not harboring EGFR mutation

about

Comparative study analyzing survival and safety of bevacizumab/carboplatin/paclitaxel and cisplatin/pemetrexed in chemotherapy-naïve patients with advanced non-squamous bronchogenic carcinoma not harboring EGFR mutation

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P478

P50

P577

P698

P921

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P478

P50

P577

P698

P921

P932